Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Cutlip, S. Windecker, R. Mehran, A. Boam, D. Cohen, G. Es, P. Steg, M. Morel, L. Mauri, P. Vranckx, E. Mcfadden, A. Lansky, M. Hamon, M. Krucoff, P. Serruys (2007)
Clinical End Points in Coronary Stent Trials: A Case for Standardized DefinitionsCirculation, 115
P. Kuchulakanti, William Chu, R. Torguson, P. Ohlmann, S. Rha, L. Clavijo, Sang-Wook Kim, A. Bui, N. Gevorkian, Zhenyi Xue, Kimberly Smith, J. Fournadjieva, W. Suddath, L. Satler, A. Pichard, K. Kent, R. Waksman (2006)
Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis With Sirolimus- and Paclitaxel-Eluting StentsCirculation, 113
S. Rao, Kristi O'Grady, K. Pieper, C. Granger, L. Newby, F. Werf, K. Mahaffey, R. Califf, R. Harrington (2005)
Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes.The American journal of cardiology, 96 9
Salah-Eddine Hassani, R. Wolfram, P. Kuchulakanti, Zhenyi Xue, N. Gevorkian, W. Suddath, L. Satler, K. Kent, A. Pichard, N. Weissman, R. Waksman (2006)
Percutaneous coronary intervention with drug‐eluting stents in octogenarians: Characteristics, clinical presentation, and outcomesCatheterization and Cardiovascular Interventions, 68
D. Peake (1988)
Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinaseJournal of Emergency Medicine, 6
J. Chesebro, G. Knatterud, R. Roberts, J. Borer, L. Cohen, J. Dalen, H. Dodge, C. Francis, D. Hillis, P. Ludbrook (1987)
Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.Circulation, 76 1
P. Roy, L. Bonello, R. Torguson, Teruo Okabe, Tina Slottow, D. Steinberg, Kimberly Kaneshige, Zhenyi Xue, L. Satler, K. Kent, W. Suddath, A. Pichard, J. Lindsay, R. Waksman (2009)
Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation.The American journal of cardiology, 103 6
G. Stone, J. Moses, S. Ellis, J. Schofer, K. Dawkins, M. Morice, A. Colombo, E. Schampaert, E. Grube, A. Kirtane, D. Cutlip, M. Fahy, S. Pocock, R. Mehran, M. Leon (2007)
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.The New England journal of medicine, 356 10
M. Pfisterer, H. Rocca, P. Buser, P. Rickenbacher, P. Hunziker, C. Mueller, R. Jeger, F. Bader, S. Osswald, C. Kaiser (2006)
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.Journal of the American College of Cardiology, 48 12
R. Waksman, A. Buch, R. Torguson, Zhenyi Xue, Kimberly Smith, A. Javaid, William Chu, L. Satler, K. Kent, A. Pichard (2007)
Long-term clinical outcomes and thrombosis rates of sirolimus-eluting versus paclitaxel-eluting stents in an unselected population with coronary artery disease (REWARDS registry).The American journal of cardiology, 100 1
H. Diener, J. Bogousslavsky, L. Brass (2004)
Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): Randomized, double-blind, placebo-controlled trialAcc Current Journal Review, 13
A. Latib, N. Morici, J. Cosgrave, F. Airoldi, C. Godino, N. Brambilla, A. Chieffo, E. Bonizzoni, M. Carlino, F. Bedogni, M. Montorfano, G. Sangiorgi, C. Briguori, A. Colombo (2008)
Incidence of bleeding and compliance on prolonged dual antiplatelet therapy (aspirin + thienopyridine) following drug-eluting stent implantation.The American journal of cardiology, 102 11
H. Diener, J. Bogousslavsky, L. Brass, C. Cimminiello, L. Csiba, M. Kaste, D. Leys, J. Matías-Guiu, H. Rupprecht (2004)
Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trialThe Lancet, 364
A. Ong, E. Mcfadden, E. Regar, P. Jaegere, R. Domburg, P. Serruys (2005)
Late angiographic stent thrombosis (LAST) events with drug-eluting stents.Journal of the American College of Cardiology, 45 12
E. Eisenstein, K. Anstrom, D. Kong, L. Shaw, R. Tuttle, D. Mark, J. Kramer, R. Harrington, D. Matchar, D. Kandzari, E. Peterson, K. Schulman, R. Califf (2007)
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.JAMA, 297 2
Sidney Smith, T. Feldman, J. Hirshfeld, A. Jacobs, M. Kern, S. King, D. Morrison, W. O'Neil, H. Schaff, P. Whitlow, David Williams, E. Antman, C. Adams, Jeffrey Anderson, D. Faxon, V. Fuster, J. Halperin, L. Hiratzka, S. Hunt, Rick Nishimura, J. Ornato, R. Page, B. Riegel (2006)
ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention).Circulation, 113 7
Sidney Smith, T. Feldman, J. Hirshfeld, A. Jacobs, M. Kern, S. King, D. Morrison, W. O’Neill, H. Schaff, P. Whitlow, David Williams, E. Antman, C. Adams, Jeffrey Anderson, D. Faxon, V. Fuster, J. Halperin, L. Hiratzka, S. Hunt, Rick Nishimura, J. Ornato, R. Page, B. Riegel (2006)
ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary InterventionCirculation, 113 1
P. Berger, M. Bell, C. Rihal, Henry Ting, G. Barsness, K. Garratt, Victoria Bellot, V. Mathew, S. Melby, L. Hammes, D. Grill, D. Holmes (1999)
Clopidogrel versus ticlopidine after intracoronary stent placement.Journal of the American College of Cardiology, 34 7
P. Groeneveld, M. Matta, Alexis Greenhut, Feifei Yang (2008)
Drug-eluting compared with bare-metal coronary stents among elderly patients.Journal of the American College of Cardiology, 51 21
J. Cheng, Y. Onuma, N. Piazza, R. Nuis, R. Domburg, P. Serruys (2010)
Comparison of five-year outcome of octogenarians undergoing percutaneous coronary intervention with drug-eluting versus bare-metal stents (from the RESEARCH and T-SEARCH Registries).The American journal of cardiology, 106 10
G. Tanzilli, C. Greco, F. Pelliccia, V. Pasceri, F. Barillà, V. Paravati, G. Pannitteri, C. Gaudio, E. Mangieri (2009)
Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study).The American journal of cardiology, 104 10
J. Eikelboom, S. Mehta, Sonia Anand, C. Xie, K. Fox, S. Yusuf (2006)
Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary SyndromesCirculation, 114
A. Segev, B. Strauss, M. Tan, C. Constance, A. Langer, S. Goodman (2005)
Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries.American heart journal, 150 4
S. Steinhubl, Peter Berger, J. III, Edward Fry, A. Delago, C. Wilmer, E. Topol (2002)
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.JAMA, 288 19
MarcoValgimigli, GianlucaCampo, MoniaMonti, PascalVranckx, GianfrancoPercoco, CarloTumscitz, FaustoCastriota, FedericoColombo, MatteoTebaldi, GiuseppeFucà, Moh'dKubbajeh, ElisaCangiano, MonicaMinarelli, AntonellaScalone, CaterinaCavazza, AliceFrangione, MarcoBorghesi, JleniaMarchesini, GiovanniParrinello, RobertoFerrari (2012)
Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting
E. Nikolsky, R. Mehran, E. Aymong, G. Mintz, A. Lansky, Zoran Lasić, M. Negoita, M. Fahy, S. Pocock, Yingbo Na, S. Krieger, J. Moses, G. Stone, M. Leon, G. Dangas (2004)
Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions.The American journal of cardiology, 94 8
M. Bertrand, H. Rupprecht, P. Urban, A. Gershlick (2000)
Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS).Circulation, 102 6
X. Álvarez, A. González (2007)
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events, 14
M. Valgimigli, G. Campo, M. Monti, P. Vranckx, G. Percoco, C. Tumscitz, F. Castriota, F. Colombo, M. Tebaldi, G. Fucà, M. Kubbajeh, E. Cangiano, Monica Minarelli, A. Scalone, Caterina Cavazza, A. Frangione, M. Borghesi, J. Marchesini, G. Parrinello, R. Ferrari (2012)
Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter TrialCirculation, 125
J. Dean, Zhou Yujie, Yingxin Zhao, Yuyang Liu, Yonghe Guo, Wanjun Cheng, C. Zheng (2009)
Prolonged Dual Antiplatelet Therapy Improves Clinical Outcomes in High‐risk Patients Implanted with Sirolimus‐eluting StentsClinical Cardiology, 32
Sidney Smith, T. Feldman, J. Hirshfeld, A. Jacobs, M. Kern, S. King, D. Morrison, W. O’Neill, H. Schaff, P. Whitlow, David Williams, E. Antman, C. Adams, Jeffrey Anderson, D. Faxon, V. Fuster, J. Halperin, L. Hiratzka, S. Hunt, Rick Nishimura, J. Ornato, R. Page, B. Riegel (2006)
ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention).Journal of the American College of Cardiology, 47 1
Objectives To evaluate the risk of long‐term dual antiplatelet therapy (DAT) following drug‐eluting stent (DES) implantation in octogenarians. Background DES implantation requires DAT; however, DAT‐associated risk in octogenarians remains unclear. Methods Two‐hundred and six consecutive octogenarians (130 men, 83.3 ± 3.4 years) underwent stent implantation (104 bare metal stents (BMSs) and 102 DESs) and 38.0 ± 13.2 months of follow‐up. Results Significantly more DES patients received DAT. The incidence of bleeding events was similar in the DES and BMS groups for 1 year (total: 10.8% vs 5.8%, P = 0.19; major: 4.9% vs 2.9%, P = 0.70). However, after 2 years, significantly more bleeding events occurred in the DES group than the BMS group (total: 2 years, 21.6% vs 9.6%, P = 0.02; 3 years, 29.4% vs 11.5%, P = 0.001; 4 years, 31.4% vs 15.4%, P = 0.007; major: 2 years, 12.7% vs 3.8%, P = 0.04; 3 years, 18.6% vs 5.8%, P = 0.005; 4 years, 19.6% vs 6.7%, P = 0.006). Overall, significantly more total bleeding events (31.4% vs 15.4%, P = 0.007) and major bleeding events (19.2% vs 6.7%, P = 0.006) were observed in the DES group than in the BMS group. The adjusted hazard ratios and 95% confidence intervals (CI) were as follows: total bleeding events, 2.203 (95% CI: 1.065–4.556; P = 0.033); major bleeding events, 4.324 (1.506–12.414; P = 0.007). Conclusions DAT was associated with an increased risk of bleeding events in octogenarians after 2 years. DAT discontinuation should be considered for octogenarians 1‐year post‐DES implantation. (J Interven Cardiol 2013;26:114–122)
Journal of Interventional Cardiology – Wiley
Published: Apr 1, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.